A case report of tumor heterogeneity after neoadjuvant chemotherapy for refractory locally advanced triple-negative breast cancer
The clinical manifestations,pathological characteristics,neoadjuvant treatment plan,heterogeneity changes in tumor genes,Miller-Payne(MP)classification,and surgery and other treatment plans of a patient with refractory locally advanced triple-negative breast cancer admitted to General Surgery,Tianjin Medical University General Hospital were analyzed.A specific subgroup of refractory locally advanced triple-negative breast cancer patients experiences molecular subtype conversion and molecular gene heterogeneity changes after neoadjuvant chemotherapy,which enhances the sensitivity of triple-negative breast cancer patients to conventional resistant chemotherapy regimens and improves their final comprehensive treatment decision-making.This kind of disease is relatively rare in actual clinical treatment,and it is easy for certain groups of people to be misdiagnosed and delayed in treatment.It helps to gradually form a consensus on treatment to summarize this kind of cases.
Neoadjuvant chemotherapyTumor gene heterogeneityTriple-negative breast cancerGene
万方数据
维普
